Yang Zhang(张阳)

Show Academic Trajectory

Ego Network

D-Core

Research Interests

Author Statistics

Experience

Education

Bio

None

Papers23 papers

Sort

By YearBy Citation

A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.

Xiao-Li Wei,Chao Ren,Feng-Hua Wang,Yang Zhang,Hong-Yun Zhao, Ben-Yan Zou,Zhi-Qiang Wang,Miao-Zhen Qiu,Dong-Sheng Zhang,Hui-Yan Luo,Feng Wang, Sheng Yao

Cancer communications (London, England), (2020)

WOSBibtex

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer.

Zhonghan Zhang,Yang Zhang, Fan Luo,Yuxiang Ma,Wenfeng Fang, Jing Zhan,Su Li,Yunpeng Yang,Yuanyuan Zhao,Shaodong Hong,Ting Zhou,Yaxiong Zhang

Clinical and translational medicine, (2020)

WOSBibtex

KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small-Cell Lung Cancer.

Yuxiang Ma,Wenfeng Fang,Yang Zhang,Yunpeng Yang,Shaodong Hong,Yuanyuan Zhao, Shuang Xie, Jun Ge, HaoJin Zhou,Hongyun Zhao,Li Zhang

The oncologist, (2020)

WOSBibtex

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).

Zhonghan Zhang, Fan Luo,Yang Zhang,Yuxiang Ma,Shaodong Hong,Yunpeng Yang,Wenfeng Fang,Yan Huang,Li Zhang,Hongyun Zhao

Cancer communications (London, England), no. 1 (2019): 69

WOSBibtex

A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.

Xing Zhang, Xizhi Wen, Chen Yang, Shan Zeng, Lichuang Men, Hengbang Wang,Yuxiang Ma,Yang Zhang, Ruiqing Peng, Desheng Weng,Li Zhang, Jiao Ji

Journal of Clinical Oncology, (2019): 3124-3124

Bibtex

Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution

Fan Luo, Zhonghan Zhang, Kunlun Liao,Yang Zhang,Yuxiang Ma,Zhihuang Hu, Kangmei Zeng,Yan Huang,Li Zhang,Hongyun Zhao

Annals of Translational Medicine, (2019)

WOSBibtex

Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation study.

Wenfeng Fang,Yuxiang Ma,Jianjin Huang,Yang Zhang, Benyan Zou,Hongyun Zhao,Yunpeng Yang,Yan Huang, Jing Zhao,Lieming Ding,Fenlai Tan,Li Zhang

Journal of Clinical Oncology, (2018)

Bibtex

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.

Yuxiang Ma,Xin Zheng,Hongyun Zhao,Wenfeng Fang,Yang Zhang, Jieying Ge, Lu Wang, Weicong Wang,Ji Jiang,Shaokun Chuai, Zhou Zhang,Wanhong Xu

Journal of thoracic oncology : official publication of the International Association for the Study o..., (2018)

Cited by7WOSBibtex

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.

Wenfeng Fang,Yunpeng Yang,Yuxiang Ma,Shaodong Hong, Lizhu Lin, Xiaohui He,Jianping Xiong, Ping Li,Hongyun Zhao,Yan Huang,Yang Zhang,Likun Chen

The Lancet. Oncology, (2018)

Cited by5WOSBibtex

A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.

Rui-hua Xu, Li Y, Jiao Ji,Miaozhen Qiu,Yang Zhang, Wenqin Liu, Xiaohong Tian,Su Li, Hengbang Wang,Fenghua Wang, Dongsheng Zhang,Feng Wang

Journal of Clinical Oncology, (2018): 2593-2593

Cited by1Bibtex

A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).

Hongyun Zhao, Zhonghan Zhang, Fan Luo,Yuxiang Ma,Wenfeng Fang,Yunpeng Yang,Yang Zhang,Yan Huang,Li Zhang

Journal of Clinical Oncology, (2018)

Bibtex

RealPoint3D: Point Cloud Generation from a Single Image with Complex Background.

Yan Xia,Yang Zhang,Dingfu Zhou,Xinyu Huang,Cheng Wang,Ruigang Yang

arXiv: Computer Vision and Pattern Recognition, (2018)

Cited by1EIBibtex

A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.

Rui-hua Xu, Dongsheng Zhang,Lin Shen, Li Jin, Jing Huang,Jifang Gong,Weijian Guo,Yang Zhang, Songhua Fan, Ke Li, Ye Hua,Weiguo Su

Journal of Clinical Oncology, (2017): 128-128

Bibtex

Correction to: Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma

Yuxiang Ma, Yuehao Lin, Benyan Zou, Wanli Liu,Yang Zhang,Liping Zhao,Yan Huang,Yunpeng Yang,Wenfeng Fang,Yuanyuan Zhao,Jin Sheng,Tao Qin

Clinical Pharmacokinetics, no. 1 (2017): 103-104

Bibtex

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.

Xiaobo He,Yang Zhang,Yuxiang Ma,Ting Zhou,Jianwei Zhang,Shaodong Hong,Jin Sheng, Zhonghan Zhang,Yunpeng Yang,Yan Huang,Li Zhang,Hongyun Zhao

Medicine, no. 31 (2016)

WOSBibtex

Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.

Yan Huang,Wenhua Liang,Yunpeng Yang,Liping Zhao,Hongyun Zhao,Xuan Wu,Yuanyuan Zhao,Yang Zhang,Li Zhang

BMC cancer, no. 1 (2016): 464

WOSBibtex

Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.

Yuxiang Ma,Yuehao Lin, Benyan Zou, Wanli Liu,Yang Zhang,Liping Zhao,Yan Huang,Yunpeng Yang,Wenfeng Fang,Yuanyuan Zhao,Jin Sheng,Tao Qin

Clinical pharmacokinetics, no. 10 (2016): 1205-1216

WOSBibtex

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment

Li Zhang,Hongyun Zhao, Jieying Ge,Yuanyuan Zhao,Wenfeng Fang,Yang Zhang,Zhihuang Hu,Lie Zheng,Ting Zhou

Scientific Reports, (2015)

Bibtex

Quality control of clinical trial institution and the analysis of influence factors

Yang Zhang,Hong Yun Zhao,Ye Cao,Ying Guo, Jian Sun,Su Li,Li Zhang,Ming Huang Hong

Chinese Journal of New Drugs, no. 22 (2014): 2643-2646

Bibtex

Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.

Li Zhang,Su Li,Yang Zhang,Jing Zhan,Ben-Yan Zou,Robert Smith,Paul D Martin,Yinrui Jiang,Hai Liao,Zhongzhen Guan

Clinical therapeutics, no. 3 (2011): 315-327

Cited by31WOSSCOPUSBibtex

View All

Base Info Papers Patents Projects